At Close: Dec 01, 2023
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know11:17am, Tuesday, 31'st Oct 2023
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now07:03am, Thursday, 19'th Oct 2023
In rough markets it's important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy g
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?06:46am, Wednesday, 27'th Sep 2023
Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today02:17pm, Tuesday, 26'th Sep 2023
The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?02:11pm, Tuesday, 26'th Sep 2023
Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly adding to those gains. Catapulting the biopharmaceutic
Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal11:42am, Tuesday, 26'th Sep 2023
Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specializing in rare and serious liver diseases announce
Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium08:12am, Tuesday, 26'th Sep 2023
Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that valu
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y11:57am, Wednesday, 02'nd Aug 2023
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript11:28am, Wednesday, 02'nd Aug 2023
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - Pr
Intercept (ICPT) to Restructure Operations, Cut Workforce02:16pm, Monday, 26'th Jun 2023
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.
Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA01:24pm, Friday, 23'rd Jun 2023
Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
Intercept to reduce work force by one third as it aims for profitability06:49am, Friday, 23'rd Jun 2023
Intercept Pharmaceuticals Inc. ICPT, -1.62% on Friday said it will reduce its work force by one third as part of its plan to reach profitability in 2024. The layoffs will affect about 110 employees, b
US FDA declines to approve Intercept's fatty liver disease drug06:00pm, Thursday, 22'nd Jun 2023
The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for Intercept Pharmaceuticals' drug to treat a type of fatty liver disease.
Intercept (ICPT) Announces Positive Data From PBC Study03:49pm, Wednesday, 07'th Jun 2023
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)08:56am, Friday, 26'th May 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.